Nostrum Pharmaceuticals Inc., Institute of Microbial Technology deal

Nostrum received an exclusive worldwide license from the institute to develop and commercialize clot-specific streptokinase (CSSK), a recombinant streptokinase for dissolving blood clots. The company ...